| Trial ID: | L2603 |
| Source ID: | NCT00730392
|
| Associated Drug: |
Etanercept
|
| Title: |
Etanercept in New Onset Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: Etanercept|DRUG: Placebo
|
| Outcome Measures: |
Primary: The primary end points of this study are percent change from baseline for HbA1c and C-peptide area under the curve (AUC)., At baseline and at the end of the 24-week blind treatment | Secondary: Secondary end points are insulin dose and number of insulin injection discontinued, if any, At baseline and at end of the 24-week treatment period
|
| Sponsor/Collaborators: |
Sponsor: State University of New York at Buffalo | Collaborators: Amgen
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2002-10
|
| Completion Date: |
2008-01
|
| Results First Posted: |
|
| Last Update Posted: |
2023-04-28
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00730392
|
